Agnès Pasquet

Prof. Agnès Pasquet

Cardiology / adult congenital heart disease, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Brussels-Capital Region, Belgium
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in European Heart Journal
Verified
Journal Article
Closed access
LMLucia Mazzolai
Lucia Mazzolai
GTGisela Teixido-Tura
Gisela Teixido-Tura
SLStefano Lanzi
Stefano Lanzi
VBVinko Boc
Vinko Boc
EBEduardo Bossone
Eduardo Bossone
MSMaksym Sokolov
Maksym Sokolov

13 August 2020 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
LHLaura Houard
Laura Houard
SMSebastian Militaru
Sebastian Militaru
KTKaoru Tanaka
Kaoru Tanaka
Agnès PasquetAgnès Pasquet
Agnès Pasquet
DVDavid Vancraeynest
David Vancraeynest
BGBernhard L Gerber
Bernhard L Gerber
Aims : Reproducible evaluation of left (LV) and right ventricular (RV) function is crucial for clinical decision-making and risk stratification. We evaluated whether speckle-tracking echocardiography (STE) and cardiac magnetic resonance feature-tracking (cMR-FT) global longitudinal (GLS) and circumferential strains allow better test–retest reproducibility of LV and RV systolic function than conventional cMR and echocardiographic parameters. Methods and results : Thirty healthy volunteers and 20 chronic heart failure patients underwent cMR and STE twice on separate days to evaluate test–retest coefficient of variation (CV), intraclass correlation coefficient (ICC) and estimated sample sizes for significant changes in LV and RV function. Among LV parameters, cMR-left ventricular ejection fraction (LVEF) had the highest reproducibility (CV = 6.7%, ICC = 0.98), significantly better than cMR-FT-GLS (CV = 15.1%, ICC = 0.84), global circumferential strains (CV = 11.5%, ICC = 0.94) and echocardiographic LVEF (CV = 11.3%, ICC = 0.93). STE-LV-GLS (CV = 8.9%, ICC = 0.94) had significantly better reproducibility than cMR-FT-LV-GLS. Among RV parameters, STE-RV-GLS (CV = 7.3%, ICC = 0.93) had significantly better CV than cMR-right ventricular ejection fraction (RVEF) (CV = 13%, ICC = 0.82). cMR-FT-RV-GLS (CV = 43%, ICC = 0.39) performed poorly with significantly lower reproducibility than all other RV parameters. Owing to their superior interstudy reproducibility, cMR-LVEF (n = 12), cMR-RVEF (n = 41), STE-LV-GLS and STE-RV-GLS (both n = 14) were the parameters allowing the lowest calculated sample sizes to detect 10% change in LV or RV systolic function. Conclusion : STE-LV-GLS and STE-RV-GLS showed higher test–retest reliability than other echocardiographic measurements of LV and RV function. They also allowed smaller calculated sample sizes, supporting the use of STE-LV and RV-GLS for longitudinal follow-up of LV and RV function.

10 May 2017 in Blood Pressure
Verified
Journal Article
Open access
LJLotte Jacobs
Lotte Jacobs
APAlexandre Persu
Alexandre Persu
QHQi-Fang Huang
Qi-Fang Huang
JLJean-Philippe Lengelé
Jean-Philippe Lengelé
LTLutgarde Thijs
Lutgarde Thijs
TDThe European Network Coordinating Research on Renal Denervation
The European Network Coordinating Research on Renal Denervation
Objective: Previous trials of catheter-based renal-artery denervation (RDN) as treatment modality in resistant hypertension (rHT) generated unconvincing results. In the Investigator-Steered Project on Intravascular Denervation for Management of Treatment-Resistant Hypertension (INSPiRED; NCT01505010), we optimized selection and management of rHT patients. Methods: With ethical clearance to randomize 18 patients, three Belgian hypertension centers screened 29 rHT patients on treatment with ≥3 drugs, of whom 17 after optimization of treatment (age <70 years; systolic/diastolic office blood pressure (BP) ≥ 140/90 mm Hg; 24-h BP ≥130/80 mm Hg; glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2; body mass index <40kg/m2) were randomized and 15 were analyzed 6 months later, while medical treatment was continued (n = 9) or combined with RDN by the EnligHTN™ multi-electrode system (n = 6). Results: The baseline-adjusted between-group differences amounted to 19.5/10.4 mm Hg (change in control vs. intervention group, +7.6/+2.2 vs. −11.9/−8.2 mm Hg; P = .088) for office BP, 22.4/13.1 mm Hg (+0.7/+0.3 vs. −21.7/−12.8; mm Hg; P ≤ .049) for 24-h BP, the primary efficacy endpoint, and 2.5 mL/min/1.73 m2 (+1.5 vs. −1.1 mL/min/1.73 m2; P = .86) for eGFR, the primary safety endpoint. At 6 month, ECG voltages and the number of prescribed drugs (P ≤ .036) were lower in RDN patients, but quality of life and adherence, captured by questionnaire and urine analysis were similar in both groups. Changes in BP and adherence were unrelated. No major complications occurred. Conclusions: The INSPiRED pilot suggests that RDN with the EnligHTN™ system is effective and safe and generated insights useful for the design of future RDN trials.

1 August 2015 in The American Journal of Cardiology
Verified
Journal Article
Closed access
CTChristophe Tribouilloy
Christophe Tribouilloy
DRDan Rusinaru
Dan Rusinaru
Vincent CharlesVincent Charles
Vincent Charles
JBJamila Boulif
Jamila Boulif
FMFrédéric Maes
Frédéric Maes
JVJean-Louis Vanoverschelde
Jean-Louis Vanoverschelde

1 October 2019 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
SMSylvestre Maréchaux
Sylvestre Maréchaux
DRDan Rusinaru
Dan Rusinaru
AAAlexandre Altes
Alexandre Altes
Agnès PasquetAgnès Pasquet
Agnès Pasquet
JVJean Louis Vanoverschelde
Jean Louis Vanoverschelde
CTChristophe Tribouilloy
Christophe Tribouilloy
Background: Grading of severe (aortic valve area ≤1 cm 2 ) aortic stenosis with preserved left ventricular ejection fraction is based on a classification depending on flow (normal flow versus low flow) and pressure gradient (low gradient versus high gradient). The aim of the present study was to compare the outcome of patients with normal flow high gradient and low flow high gradient severe aortic stenosis (SAS) with no or minimal symptoms. Methods: This multicenter study enrolled 983 consecutive patients (mean age 75±11 years, 459 women) with asymptomatic or minimally symptomatic HG (mean pressure gradient ≥40 mm Hg) SAS with preserved left ventricular ejection fraction. Low flow was defined by Doppler echocardiography as a stroke volume index <30 mL/m 2 (n=131) or a stroke volume <55 mL (n=136). The end point was all-cause mortality. Results: During a median follow-up period of 48 (45–52) months, 225 patients (23%) died. The 60–month mortality was higher in low flow high gradient SAS compared with normal flow high gradient SAS (36±5% versus 22±2% and 38±5% versus 21±2% for stroke volume index and stroke volume, respectively, both P <0.0001). After adjustment for outcome predictors including aortic valve replacement as time-dependent covariate, low flow high gradient SAS displayed considerable mortality risk during follow up compared with normal flow high gradient SAS (adjusted HR 2.17 [1.51–3.13]; P <0.0001 for stroke volume index <30 mL/m 2 and adjusted HR 1.86 [1.29–2.68]; P =0.001, for stroke volume <55 mL). The prognostic impact of low flow was consistent in subgroups of patients. Conclusions: Asymptomatic or minimally symptomatic patients with low flow high gradient SAS and preserved left ventricular ejection fraction have a considerable increased risk of mortality during follow-up. These patients should be promptly considered for aortic valve replacement.

3 April 2019 in Blood Pressure
Verified
Journal Article
Closed access
CWCora Wunder
Cora Wunder
APAlexandre Persu
Alexandre Persu
JLJean-Philippe Lengelé
Jean-Philippe Lengelé
CGCoralie Mg Georges
Coralie Mg Georges
JRJean Renkin
Jean Renkin
TTThe European Network Coordinating Research on Renal Denervation (ENCOReD), Stefan W. Toennes
The European Network Coordinating Research on Renal Denervation (ENCOReD), Stefan W. Toennes
Purpose: Drug adherence may be a major problem in the therapy of hypertension and in the diagnosis of therapy resistance. Adherence can be assessed by indirect methods or by direct methods like drug detection in urine with liquid chromatography-mass spectrometric methods. Materials and methods: The current analysis included patients with apparently treatment- resistant hypertension (TRH) referred for renal denervation (RDN) and included in the the INSPiRED pilot trial (NCT 01505010). Adherence was repeatedly assessed by toxicological urine analysis over a time range of up to 17 months in a total of 18 patients. Results: In the first urine samples of 18 patients the adherence rate (percentage of number of detected vs. prescribed medical drugs) ranged from 0 to 100% with a median of 73.2%. In further urine samples collected during the following up to 17 months every individual patient exhibited considerable changes in the adherence rate, neither a constancy nor a tendency could be deduced. Conclusions: Urine analysis results exhibit variation over time and an assessment at a certain time point cannot be regarded as representative or predictor for future behavior. Therefore, it appears necessary to perform drug adherence testing repeatedly over time.